HWPC(SH:688799) Xin Lang Cai Jing·2025-11-17 01:29Core Insights - Warner Pharmaceutical's stock price decreased by 0.67% on November 14, with a trading volume of 161 million yuan [1] - The company reported a net profit growth of 30.75% year-on-year for the first nine months of 2025, reaching 207 million yuan [2] Financing and Margin Trading - On November 14, Warner Pharmaceutical had a financing buy-in amount of 24.6 million yuan and a net buy of 3.35 million yuan, with a total financing balance of 353 million yuan, accounting for 5.17% of its market capitalization [1] - The financing balance is above the 70th percentile of the past year, indicating a high level of financing activity [1] Shareholder and Institutional Holdings - As of September 30, 2025, the number of shareholders decreased by 11.83% to 6,416, while the average circulating shares per person increased by 13.42% to 20,467 shares [2] - The company has distributed a total of 291 million yuan in dividends since its A-share listing, with 225 million yuan distributed over the past three years [3] Business Overview - Warner Pharmaceutical, established on April 30, 2001, specializes in the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - The revenue composition includes 73.19% from formulations, 25.22% from raw materials and intermediates, and 1.52% from technical services [1]